Aerius

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
02-08-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
02-08-2023

Aktiivinen ainesosa:

desloratadine

Saatavilla:

N.V. Organon

ATC-koodi:

R06AX27

INN (Kansainvälinen yleisnimi):

desloratadine

Terapeuttinen ryhmä:

Antihistamines for systemic use,

Terapeuttinen alue:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Käyttöaiheet:

Aerius is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.

Tuoteyhteenveto:

Revision: 50

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2001-01-15

Pakkausseloste

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AERIUS 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aerius is and what it is used for
2.
What you need to know before you take Aerius
3.
How to take Aerius
4.
Possible side effects
5.
How to store Aerius
6.
Contents of the pack and other information
1.
WHAT AERIUS IS AND WHAT IT IS USED FOR
WHAT AERIUS IS
Aerius contains desloratadine which is an antihistamine.
HOW AERIUS WORKS
Aerius is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN AERIUS SHOULD BE USED
Aerius relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages caused
by an allergy, for example, hay fever or allergy to dust mites) in
adults and adolescents 12 years of age
and older. These symptoms include sneezing, runny or itchy nose, itchy
palate, and itchy, red or
watery eyes.
Aerius is also used to relieve the symptoms associated with urticaria
(a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AERIUS
DO NOT TAKE AERIUS
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Aerius:
-

                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aerius 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aerius is indicated in adults and adolescents aged 12 years and older
for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Aerius is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_ _
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Aerius 5 mg film-coated tablets in children
below the age of 12 years have
not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function impairment
In th
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 02-08-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 09-06-2015
Pakkausseloste Pakkausseloste espanja 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 02-08-2023
Pakkausseloste Pakkausseloste tšekki 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 02-08-2023
Pakkausseloste Pakkausseloste tanska 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 02-08-2023
Pakkausseloste Pakkausseloste saksa 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 02-08-2023
Pakkausseloste Pakkausseloste viro 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto viro 02-08-2023
Pakkausseloste Pakkausseloste kreikka 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 02-08-2023
Pakkausseloste Pakkausseloste ranska 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 02-08-2023
Pakkausseloste Pakkausseloste italia 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto italia 02-08-2023
Pakkausseloste Pakkausseloste latvia 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 02-08-2023
Pakkausseloste Pakkausseloste liettua 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 02-08-2023
Pakkausseloste Pakkausseloste unkari 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 02-08-2023
Pakkausseloste Pakkausseloste malta 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto malta 02-08-2023
Pakkausseloste Pakkausseloste hollanti 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 02-08-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 09-06-2015
Pakkausseloste Pakkausseloste puola 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto puola 02-08-2023
Pakkausseloste Pakkausseloste portugali 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 02-08-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 09-06-2015
Pakkausseloste Pakkausseloste romania 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto romania 02-08-2023
Pakkausseloste Pakkausseloste slovakki 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 02-08-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 09-06-2015
Pakkausseloste Pakkausseloste sloveeni 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 02-08-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 09-06-2015
Pakkausseloste Pakkausseloste suomi 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 02-08-2023
Pakkausseloste Pakkausseloste ruotsi 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 02-08-2023
Pakkausseloste Pakkausseloste norja 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto norja 02-08-2023
Pakkausseloste Pakkausseloste islanti 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 02-08-2023
Pakkausseloste Pakkausseloste kroatia 02-08-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 02-08-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia